FDA Orange Book · active-ingredient family
Frovatriptan succinate
Frovatriptan succinate is approved as 1 brand and 5 generic applications in the FDA Orange Book, with their therapeutic-equivalence codes, listed patents, and marketing exclusivity.
Reference-listed drug:FROVA · NDA 021006
1
Brand (NDA)
5
Generics (ANDA)
0
Listed patents
0
Exclusivity periods
Brand (NDA) products · tablet
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| FROVARLD | ENDO OPERATIONS | NDA 021006 | — | Nov 08, 2001 |
Generic (ANDA) products (5)
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| FROVATRIPTAN SUCCINATE | LEADING | ANDA 216998 | AB | Apr 16, 2025 | |
| FROVATRIPTAN SUCCINATE | RENATA | ANDA 213891 | AB | Apr 06, 2022 | |
| FROVATRIPTAN SUCCINATE | AMNEAL PHARMS CO | ANDA 211292 | AB | Nov 06, 2018 | |
| FROVATRIPTAN SUCCINATE | GLENMARK PHARMS LTD | ANDA 204730 | AB | Mar 11, 2016 | |
| FROVATRIPTAN SUCCINATE | PHARMOBEDIENT | ANDA 202931 | — | Aug 28, 2014 |
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
Frovatriptan succinate — frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.
